Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Deep Bio has developed and commercialized AI-powered digital pathology solutions for prostate cancer diagnosis that have received regulatory approval in South Korea. The company continues to expand its product suite to other cancers such as breast and bladder, with ongoing clinical collaborations and research publications demonstrating high accuracy and reproducibility of its algorithms. Clinical trials have been conducted for the "DeepDx-Prostate" solution. The company was the first in South Korea to receive MFDS approval for an AI-based cancer diagnostic support solution. Peer-reviewed publications validate the performance of their technology in real-world settings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Deep Bio.